DEHP Prop 65 listing
This article was originally published in The Rose Sheet
Executive Summary
California Office of Environmental Health Hazard Assessment announces intent to list di (2-ethylhexyl) phthalate as known to the state to cause reproductive toxicity in 1notice made available April 15. Listing is based on conclusions by the National Institute for Occupational Safety and Health and FDA demonstrating DEHP causes developmental and reproductive toxicity in laboratory animals, according to OEHHA. Objections to the listing of DEHP under Prop 65 will be accepted until May 12, agency adds. OEHHA solicited data on DEHP in 1998. A public forum was held to discuss the chemical in 1999...
You may also be interested in...
DEHP Prop 65 listing
California Office of Environmental Health Hazard Assessment lists di (2-ethylhexyl) phthalate as chemical known to the state to cause reproductive toxicity Oct. 24, agency announces. Listing based on "formal" identification by National Institute for Occupational Safety and Health and FDA that chemical causes developmental and male reproductive toxicity. OEHHA analyses of dose response data to establish a maximum allowable dose level for DEHP under Prop 65 will be designated a priority in future status report for safe harbor levels, agency reports. OEHHA announced intent to list DEHP in April in the California Regulatory Notice Register (1"The Rose Sheet" April 28, 2003, In Brief)...
Prop 65 safe harbor levels
Di(2-ethylhexyl)phthalate (DEHP) poses no significant risk at levels of 310 µg/day, according to September status report on Prop 65 safe harbor levels. Released by California's Office of Environmental Health Hazard Assessment, report also designates No Significant Risk Level for perfume ingredient Catechol as a "second priority" for the agency. Prop 65 requires safe harbor warnings on products containing ingredients known to cause cancer or reproductive toxicity. OEHHA announced its intent to add DEHP and Catechol to Prop 65 list in April and May, respectively (1"The Rose Sheet" April 28, 2003, In Brief and 2"The Rose Sheet" May 26, 2003, In Brief)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.